Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022164738 - AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

Publication Number WO/2022/164738
Publication Date 04.08.2022
International Application No. PCT/US2022/013473
International Filing Date 24.01.2022
IPC
G16H 50/70 2018.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
70for mining of medical data, e.g. analysing previous cases of other patients
G16H 20/17 2018.1
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
20ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
10relating to drugs or medications, e.g. for ensuring correct administration to patients
17delivered via infusion or injection
A61K 38/26 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
A61M 5/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
5Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
A61K 38/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
28Insulins
A61M 5/142 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
5Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
142Pressure infusion, e.g. using pumps
CPC
A61B 5/14532
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
14532for measuring glucose, e.g. by tissue impedance measurement
A61B 5/4839
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
48Other medical applications
4836Diagnosis combined with treatment in closed-loop systems or methods
4839combined with drug delivery
A61B 5/4866
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
48Other medical applications
4866Evaluating metabolism
A61B 5/7282
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes
72Signal processing specially adapted for physiological signals or for diagnostic purposes
7271Specific aspects of physiological measurement analysis
7282Event detection, e.g. detecting unique waveforms indicative of a medical condition
A61K 38/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
Applicants
  • INSULET CORPORATION [US]/[US]
Inventors
  • LEE, Joon Bok
  • O'CONNOR, Jason
  • ZHENG, Yibin
  • ZADE, Ashutosh
Agents
  • CARLETON, Dennis M.
  • BLUNI, Scott T.
Priority Data
63/143,43729.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE
(FR) SYSTÈME AUTOMATISÉ D'ADMINISTRATION D'INSULINE UTILISANT DU PRAMLINTIDE
Abstract
(EN) Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.
(FR) Sont ici divulgués des systèmes et des procédés pour l'administration d'insuline et de pramlintide à l'aide d'un système automatisé d'administration d'insuline. Dans un premier mode de réalisation, un système d'administration de médicament est configuré pour administrer des doses indépendantes d'insuline et de pramlintide. Le système surveille le taux de glycémie de l'utilisateur et détermine le moment où un repas a été ingéré et, en réponse, administre la dose de pramlintide qui, à son tour, modifie l'administration requise d'insuline. Dans le second mode de réalisation, le système d'administration de médicament est configuré pour administrer une co-formulation d'insuline et de pramlintide en tant que doses basales. La quantité totale de pramlintide administrée dans une période de temps prédéfinie la plus récente, par exemple, 24 heures, est utilisée pour modifier l'agressivité de l'algorithme qui détermine les doses basales de la co-formulation.
Latest bibliographic data on file with the International Bureau